ARGX vs DXCM
argenx SE vs Dexcom — AI-powered side-by-side comparison
| Metric | ARGX | DXCM |
|---|
| AI Score |
67
|
65
|
| Price |
$1,019.71
|
$89.16
|
| P/E Ratio |
36.97×
|
35.16×
|
| ROE |
17.6%
|
30.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
89.9%
|
62.5%
|
| Debt / Equity |
0.01×
|
0.53×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
69.2
|
65.4
|
| Beta |
-0.022
|
1.41
|
| Expected Upside |
—
|
+2.3%
|
AI Committee View
Current Innellis committee reasoning for ARGX versus DXCM.
ARGX leads by 2 points.
ARGX scores 67/100 (Buy) versus DXCM at 65/100 (Buy).
ARGX Committee View
83% agreement
6 analysts
The primary driver is revenue growing 71.3% yoy -- genuine top-line momentum. The main limiting factor is price-to-book of 6.9x prices in significant intangible value. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 22.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 71.3% YoY -- genuine top-line momentum — Growth
- EPS growing 95.7% YoY — Growth
Bear Case
- Price-to-book of 6.9x prices in significant intangible value — Value
- Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical
- Bollinger bandwidth of 32.9% signals elevated volatility — Risk
DXCM Committee View
67% agreement
6 analysts
The primary driver is eps growing 79.4% yoy. The main limiting factor is p/e of 34.5 is moderate-to-rich. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 36.2% shows genuine earnings power backing the valuation — Value
- EPS growing 79.4% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- P/E of 34.5 is moderate-to-rich — Value
- Price-to-book of 9.4x prices in significant intangible value — Value
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical